← Back to Search

Tyrosine Kinase Inhibitor

Experimental: Povorcitinib Dose A for Vitiligo

Phase 3
Recruiting
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged ≥ 18 years.
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52 and week 104
Awards & highlights

Study Summary

This trial tests if a new drug is safe and effective to treat vitiligo, a skin condition.

Who is the study for?
This trial is for adults over 18 with nonsegmental vitiligo, having a certain amount of body surface area affected. Participants must not be treating their vitiligo with other methods during the study and agree to prevent pregnancy or fathering children.Check my eligibility
What is being tested?
The trial is testing Povorcitinib's effectiveness and safety against a placebo in individuals with nonsegmental vitiligo. It aims to see if this medication can improve skin condition compared to no active treatment.See study design
What are the potential side effects?
While specific side effects are not listed here, typical drug-related side effects may include nausea, headaches, possible allergic reactions, or skin irritation at the site of application.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I agree to stop all vitiligo treatments during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52 and week 104
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 and week 104 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)
Secondary outcome measures
Change from baseline in the Hospital Anxiety and Depression Scale (HADS) subscales
Change from baseline in the Vitiligo-Specific Quality of Life (VitiQoL)
Number of participants with Treatment-emergent Adverse Events (TEAEs)
+19 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental: Povorcitinib Dose AExperimental Treatment1 Intervention
Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
365 Previous Clinical Trials
54,851 Total Patients Enrolled
9 Trials studying Vitiligo
2,068 Patients Enrolled for Vitiligo
Incyte Medical MonitorStudy DirectorIncyte Corporation
23 Previous Clinical Trials
4,628 Total Patients Enrolled
1 Trials studying Vitiligo
444 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining opportunities to partake in this research?

"According to the clinicaltrials.gov page, this research endeavour is still in need of participants. It was first posted on December 4th 2023 and underwent its last update on November 30th 2023."

Answered by AI

How many hospitals in the state are currently carrying out this research?

"77 clinical trial sites are currently running this medical study, including Csk Mswia Centralny Szpital Kliniczny Mswia in Warszawa, Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center in Sunnyvale and Cahaba Dermatology in Hoover."

Answered by AI

How many subjects are being observed in this research endeavor?

"To achieve the necessary sample size of 444 participants, Incyte Corporation is recruiting from multiple sites including Csk Mswia Centralny Szpital Kliniczny Mswia in Warszawa, Alabama and Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center in Sunnyvale, Nevada."

Answered by AI

What are the core aims of this medical study?

"Incyte Corporation, the clinical trial sponsor has set a Week 52 period to measure their main objective; Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75). Additionally, this experiment will assess secondary outcomes such as Proportion of participants achieving a Vitiligo Noticeability Scale Score (VNS) score of 4 or 5 - which reflects when lesions are 'a lot less noticeable' and even 'no longer visible'. They will also be appraising Proportion of Participants Achieving Total Body Vitiligo Area Scoring Index"

Answered by AI

What facts can you provide regarding the safety of Povorcitinib Dose A for human consumption?

"Considering the Phase 3 status of this experimental drug, our team at Power assigned a safety rating of 3 for Povorcitinib Dose A. This is because there are clinical studies proving its efficacy and multiple rounds showing it to be safe."

Answered by AI

Who else is applying?

What site did they apply to?
University of California Irvine
Clinical Research Partners Llc Crp Richmond Forest Avenue Office Building Location
Other
Cleaver Medical Group
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

Have been affected by vitiligo for over 5 years. I have only tried topicals to help resolve my Vitiligo. Prescribed Plaquenil for unspecified auto-immune condition prior to appearance of Vitiligo.
PatientReceived 2+ prior treatments

What questions have other patients asked about this trial?

What is the compensation?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
2023. "A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06113445.
All > Paid Studies Las Vegas > Spokane
~296 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top